Avant Diagnostics Inc (AVDX) stock price


In the news

Get notified when we upgrade Avant Diagnostics Inc to a recommended stock

Free of charge we provide stock recommendations. Check our Best Stocks list.

Marketing by

Table History

Company Profile

Comparison table

What is Avant Diagnostics Inc stock price today?

Who is Avant Diagnostics, Inc. (Symbol stock: AVDX)?

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company specializing in large panels and biomarker screening to provide laboratory tests for early cancer detection. The company is seeking FDA approval for an early detection test for Down Syndrome, Alzheimer's Disease, Parkinson's Disease; the test will detect many types of cancer, including breast, prostate, lung and colon, and other conditions with component genetic inheritance. In addition, the AVDX test can see over 100 genetic mutations simultaneously to provide families with the most accurate diagnosis possible.
The test analyzes stool or stool samples with the help of an automated analyzer to detect elevated levels of specific proteins associated with the presence of the disease.

Avant Diagnostics (AVDX) also develops new blood-based diagnostics products, which are scheduled for launch in 2021. With the launch of these products in 2021, the company offers investors the opportunity to invest in a company with excellent growth potential.

What is a stock forecast for Avant Diagnostics, Inc. (AVDX)?

Avant Diagnostics, Inc. (AVDX) has a market capitalization of $1.2 billion. Shares were up 20% last year as its growth strategy has been effective this year, with three acquisitions, two new lab sites, and four new lab contracts contributing to its revenue growth in 9M18 versus 9M17.

Avant Diagnostics, Inc. (AVDX) has a market cap of $13.5 million and is part of the healthcare industry. The company has a P/E ratio of 47.9 and a beta of 0.92. It is also one of the top stocks in its industry group.

Avant Diagnostics, Inc. (AVDX) is an emerging medical laboratory company. AVDX has been trading at $5.10/share for the past six months but has recently soared to $6.93/share (a 29% increase). This stock is highly volatile and can be challenging to predict due to its small market capitalization, meaning it has less liquidity than stocks with a larger market capitalization.

Avant Diagnostics (AVDX) is a clinical diagnostics company focused on the research, development, and commercialization of molecular diagnostic tests that can identify diseases in various fields of medicine.
The share price increased 18.5% last year. As a result, Wall Street analysts believe these shares should be purchased for $28.00 each.

Analysts predict an increase in Avant Diagnostics' (AVE) share price in the next 12 months. The Avant Diagnostics (AVDX) is expected to trade at $28.00 on average next year, but some experts believe it will rise to $31.00 a share, while others think it will drop to $28.00 stock.